{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:22Z","timestamp":1792791442570,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Atlantic Healthcare Limited","id":[{"id":"https:\/\/ror.org\/03tx9h743","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100008373","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"Receptos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prometheus Laboratories"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","gastrojournal.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1053\/j.gastro.2020.02.030","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T20:27:36Z","timestamp":1582316856000},"page":"2139-2149.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":261,"title":["Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis"],"prefix":"10.1053","volume":"158","author":[{"given":"William J.","family":"Sandborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1713-7797","authenticated-orcid":false,"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6902","authenticated-orcid":false,"given":"Julian","family":"Panes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0068-1283","authenticated-orcid":false,"given":"Satoshi","family":"Tanida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Siffledeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Enejosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2775","authenticated-orcid":false,"given":"Ahmed A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bidan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-4341","authenticated-orcid":false,"given":"Peter D.R.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2020.02.030_bib1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.crohns.2014.01.028","article-title":"Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease\u2014an ECCO-EpiCom study","volume":"8","author":"Burisch","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2020.02.030_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ecco-jcc\/jjv218","article-title":"Self-reported symptom burden in individuals with inflammatory bowel disease","volume":"10","author":"Farrell","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2020.02.030_bib3","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1093\/ecco-jcc\/jjx002.484","article-title":"Correlation between physician and patient disease assessments in ulcerative colitis: baseline data from the ICONIC study of 1816 patients in 33 countries","volume":"11","author":"Ghosh","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2020.02.030_bib4","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.crohns.2014.03.005","article-title":"IBD and health-related quality of life \u2014 discovering the true impact","volume":"8","author":"Lonnfors","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"issue":"9853","key":"10.1053\/j.gastro.2020.02.030_bib5","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ordas","year":"2012","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2020.02.030_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.02.030_bib7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2020.02.030_bib8","first-page":"263","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis [in Spanish]","volume":"79","author":"Dignass","year":"2014","journal-title":"Rev Gastroenterol Mex"},{"key":"10.1053\/j.gastro.2020.02.030_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","article-title":"Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort","volume":"106","author":"Vavricka","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2020.02.030_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of Janus kinase inhibitors in inflammatory bowel disease","volume":"11","author":"De Vries","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1053\/j.gastro.2020.02.030_bib11","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/1744666X.2017.1291342","article-title":"JAK inhibition in inflammatory bowel disease","volume":"13","author":"Olivera","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1053\/j.gastro.2020.02.030_bib12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.gastro.2020.02.030_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/annrheumdis-2014-eular.3823","article-title":"Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects","volume":"73","author":"Voss","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2020.02.030_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.462","article-title":"Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials","volume":"8","author":"Mohamed","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1053\/j.gastro.2020.02.030_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40262-019-00739-3","article-title":"Population pharmacokinetics of upadacitinib with the immediate release and extended release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I\u2013III clinical trials","volume":"58","author":"Kl\u00fcnder","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.gastro.2020.02.030_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In\u00a0vitro and in\u00a0vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"10066","key":"10.1053\/j.gastro.2020.02.030_bib17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"10.1053\/j.gastro.2020.02.030_bib18","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn\u2019s disease: results from Celest","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2020.02.030_bib19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nrgastro.2016.128","article-title":"Current best practice for disease activity assessment in IBD","volume":"13","author":"Walsh","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1136\/gutjnl-2015-310393","article-title":"Development and validation of a histological index for UC","volume":"66","author":"Mosli","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2020.02.030_bib21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A\u00a0phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib22","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2020.02.030_bib23","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib24","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A\u00a0phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib25","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2020.02.030_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.gastro.2020.02.030_bib27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"Suppl 10","key":"10.1053\/j.gastro.2020.02.030_bib28","first-page":"2764","article-title":"A\u00a0phase 3 randomized, placebo-controlled, double-blind study of upadacitinib (ABT-494), a selective JAK-1 inhibitor, in patients with active rheumatoid arthritis with inadequate response to conventional synthetic DMARDs","volume":"69","author":"Burmester","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 10","key":"10.1053\/j.gastro.2020.02.030_bib29","first-page":"713","article-title":"Long-term safety and efficacy of upadacitinib (ABT-494), an oral JAK-1 inhibitor in patients with rheumatoid arthritis in an open label extension study","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib30","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3748\/wjg.v20.i12.3173","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: focus on prevention and treatment","volume":"20","author":"Papa","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"9715","key":"10.1053\/j.gastro.2020.02.030_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet"},{"issue":"47","key":"10.1053\/j.gastro.2020.02.030_bib32","doi-asserted-by":"crossref","first-page":"E1438","DOI":"10.1503\/cmaj.161485","article-title":"Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-\u03b1 inhibitors or nonbiologic agents: a cohort study","volume":"189","author":"Desai","year":"2017","journal-title":"CMAJ"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2020.02.030_bib33","first-page":"357","article-title":"THU0167Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select phase 3 clinical program","volume":"78","author":"Cohen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"10.1053\/j.gastro.2020.02.030_bib34","first-page":"4042","article-title":"Herpes zoster in patients with moderate to severe rheumatoid arthritis treated with baricitinib","volume":"68","author":"Winthrop","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib35","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1053\/j.gastro.2020.02.030_bib36","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"}],"updated-by":[{"DOI":"10.1053\/j.gastro.2020.08.040","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000}}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520302419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508520302419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T09:39:37Z","timestamp":1668591577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508520302419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0016508520302419"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2020.02.030","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2020.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}